Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Cash & Equivalents (2024 - 2025)

Carlsmed (CARL) has disclosed Cash & Equivalents for 2 consecutive years, with $109.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 173.89% year-over-year to $109.9 million, compared with a TTM value of $109.9 million through Dec 2025, up 173.89%, and an annual FY2025 reading of $109.9 million, up 173.89% over the prior year.
  • Cash & Equivalents was $109.9 million for Q4 2025 at Carlsmed, down from $115.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $115.4 million in Q3 2025 and bottomed at $33.5 million in Q2 2025.